The immunogenicity and safety of live attenuated varicella-zoster virus vaccine in human immunodeficiency virusinfected children

Pediatric Infectious Disease Journal

Volumn 30, Issue 4, 2011, Pages 320-324

  Taweesith, Wattanee ^a   Puthanakit, Thanyawee ^b   Kowitdamrong, Ekasit ^a   Bunupuradah, Torsak ^b   Wongngam, Walaiporn ^b   Phasomsap, Chayapa ^b   Apornpong, Tanakorn ^b   Bouko, Channuwat ^b   Pancharoen, Chitsanu ^a  

^a CHULALONGKORN UNIVERSITY   (Thailand)

^b THAI RED CROSS AIDS RESEARCH CENTRE   (Thailand)

Author keywords

Children; Human immunodeficiency virus (HIV); Protective antibody; Varicella vaccine; Varicella zoster virus

Indexed keywords

CHICKENPOX VACCINE;

ADOLESCENT; ARTICLE; CD4 LYMPHOCYTE COUNT; CHICKENPOX; CHILD; DRUG SAFETY; ERYTHEMA; FEMALE; FEVER; HEADACHE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; IMMUNOGENICITY; IMMUNOSUPPRESSIVE TREATMENT; MAJOR CLINICAL STUDY; MALE; PAIN; PRESCHOOL CHILD; PRIORITY JOURNAL; RASH; SCHOOL CHILD; SEROCONVERSION; SKIN INDURATION; SORE THROAT; VACCINATION;

EID: 79954729206     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0b013e3181fe0868     Document Type: Article

References (21)

1. Son M, Shapiro ED, LaRussa P, et al. Effectiveness of varicella vaccine in children infected with HIV. J Infect Dis. 2010;201:1806-1810.
2. Armenian SH, Han JY, Dunaway TM, et al. Safety and immunogenicity of live varicella virus vaccine in children with Human Immunodeficiency Virus type 1. Pediatr Infect Dis J. 2006;25:368-370.
3. Admani B, Macharia WM, Were F. Seroprevalence of varicella zoster antibodies among children with malnutrition, malignancies and HIV infection. East Afr Med J. 2008;85:480-486.
4. Pancharoen C, Ananworanich J, Thisyakorn U. Immunization for persons infected with human immunodeficiency virus. Curr HIV Res. 2004;2:293-299. (Pubitemid 39242959)
5. Levin MJ. Varicella vaccination of immunocompromised children. Pediatr Infect Dis J. 2008;197:S200-S206. (Pubitemid 351590172)
6. Centers for Disease Control and Prevention (CDC), Infectious Diseases Society of America, and the American Society of Blood and Marrow Transplant. Guidelines for preventing opportunistic infection among hematopoietic stem cell transplant recipients. MMWR Recomm Rep. 2000; 49(RR-10):1-125, CE1-CE7.
7. Levin MJ, Gershon AA, Weinberg A, et al. Immunization of HIV-infected children with varicella vaccine. J Pediatr. 2001;139:305-310. (Pubitemid 32721722)
8. Levin MJ, Gershon AA, Weinberg A, et al. Administration of live varicella vaccine to HIV-infected children with current or past significant depression of CD4(+) T cells. J Infect Dis. 2006;194:247-255. (Pubitemid 44087197)
9. Puthanakit T, Oberdorfer A, Akarathum N, et al. Efficacy of highly active antiretroviral therapy in HIV-infected children participating in Thailand's National Access to Antiretroviral Program. Clin Infect Dis. 2005;41:100-107. (Pubitemid 40863751)
10. CDC. Revised classification system for human immunodeficiency virus infection in children less than 13 years of age. Morb Mortal Wkly Rep. 1994;43:1-12.
11. Division of AIDS, National Institute of Allergy and Infectious Diseases. Table for Grading the Severity of Adult and Pediatric Adverse Events Version 1.0-December 2004 (Clarification dated August 2009). Available at: http://rcc.techres.com/Document/safetyandpharmacovigilance/ DAIDSAEGradingTableClarificatonAugust2009Final.pdf.
12. Kowitdamrong E, Pancharoen C, Thammaborvorn R, et al. The prevalence of varicella-zoster virus infection in normal healthy individuals ages above 6 months. J Med Assoc Thai. 2005;88:7-11.
13. Bekker V, Westerlaken GH, Scherpbier H, et al. Varicella vaccine in HIV-1-infected after immune reconstitution. AIDS. 2006;20:2321-2329. (Pubitemid 44789534)
14. Sartori AM. A review of the varicella vaccine in immunocompromised individuals. Int J Infect Dis. 2004;8:259-270. (Pubitemid 39119849)
15. Morales-Castillo ME, Alvarez-Munoz MT, Solorzano-Santos F, et al. Live varicella vaccine in both immunocompromised and healthy children. Arch Med Res. 2000;31:85-87. (Pubitemid 30184826)
16. Hadinegoro SR, Hindra IS, Han HH, et al. Reactogenicity and immunogenicity of a live-attenuated refrigerator-stable varicella vaccine (OKA strain) in healthy seronegative subjects age 10 months to 12 years. Southeast Asian J Trop Med Public Health. 2009;40:991-999.
17. Kuter B, Matthews H, Shinefield H, et al. Ten year follow-up of healthy children who received one or two injections of varicella vaccine. Pediatr Infect Dis J. 2004;23:132-137. (Pubitemid 38222785)
18. American Academy of Pediatrics. Varicella zoster infections. In: Pickering LK, Baker CJ, Kimberlin DW, et al, eds. 2009 Red Book: Report of the Committee on Infectious Diseases. 28th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2009:714-727.
19. Gershon AA, Levin MJ, Weinberg A, et al. A phase I-II study of live attenuated varicell-zoster virus vaccine to boost immunity in human immunodeficiency virus-infected children with previous varicella. Pediatr Infect Dis J. 2009;28:653-655.
20. Chaves SS, Haber P, Walton K, et al. Safety of varicella vaccine after licensure in the United States: experience from reports to the vaccine adverse event reporting system, 1995-2005. J Infect Dis. 2008;197:S170-S177. (Pubitemid 351590167)
21. Aurpibul L, Puthanakit T, Sirisanthana T, et al. Persistence of measles, mumps, and rubella protective antibodies 3 years after revaccination in HIV-infected children receiving antiretroviral therapy. Clin Infect Dis. 2010;50:1415-1418.